Joshua Zeidner, MD (IMAGE)
Caption
“Immunotherapy has led to a paradigm shift in treating cancer, but acute myeloid leukemia has lagged behind other cancers despite extensive data that it may be effective," Zeidner said. "Our study is the first clinical trial to investigate the role of pembrolizumab in combination with intensive chemotherapy in patients with acute myeloid leukemia that relapses or is resistant to therapy.”
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content